COPD: Journal of Chronic Obstructive Pulmonary Disease最新文献

{"title":"Burden of Chronic Obstructive Pulmonary Disease in China: A Global Burden of Disease Study on Temporal Trends, Risk Factor Contributions, and Projected Disease Burden from 1990 to 2030.","authors":"Jiaman Liao, Longsheng Zeng, Xueliang Huang, Hao Huang, Cuina Shen, Jing Li, Yiqiang Zhan","doi":"10.1080/15412555.2025.2531016","DOIUrl":"https://doi.org/10.1080/15412555.2025.2531016","url":null,"abstract":"<p><p>Chronic obstructive pulmonary disease (COPD) is a major public health issue in China, but comprehensive studies on its long-term trends, risk factors, and future projections are limited. This study aimed to assess the COPD burden in China from 1990 to 2021, analyze risk factor contributions across demographic subgroups, and project future trends through 2030 to inform public health interventions. Data from the Global Burden of Disease Study 2021 were analyzed for incidence, prevalence, mortality, and disability-adjusted life years (DALYs). Joinpoint regression was used to calculate age-standardized rates, population attributable fractions (PAFs) assessed risk factor contributions, and ARIMA modeling projected future trends. From 1990 to 2021, the age-standardized incidence, prevalence, mortality, and DALYs rates of COPD showed a declining trend, while the absolute burden increased due to population growth and aging. Men had a higher overall disease burden, but since 2015, women have shown higher age-standardized prevalence. The highest burden was observed in the ≥80 age group, with a worrying rise in age-standardized mortality in the 20-24 age group. Smoking was a major risk factor for men, while ambient particulate matter pollution had a greater impact on women and younger adults (30-34 years). Projections suggest a decreasing trend for most age groups, while the 30-39 and ≥80 age groups will experience an increase in age-standardized incidence rates. These findings highlight the need for targeted public health strategies focusing on tobacco control, air pollution, and climate-related exposures, with emphasis on age and sex differences.</p>","PeriodicalId":10704,"journal":{"name":"COPD: Journal of Chronic Obstructive Pulmonary Disease","volume":"22 1","pages":"2531016"},"PeriodicalIF":2.2,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144625540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lung Function Decline in COPD - Relations to Changes in Symptom Burden, Inflammation, and Comorbidities.","authors":"Juan Wang, Björn Ställberg, Maria Hårdstedt, Kristina Bröms, Margareta Gonzalez Lindh, Amir Farkhooy, Andreas Palm, Karin Lisspers, Marieann Högman, Andrei Malinovschi","doi":"10.1080/15412555.2025.2525433","DOIUrl":"https://doi.org/10.1080/15412555.2025.2525433","url":null,"abstract":"<p><strong>Purpose: </strong>The study aims to improve the knowledge on the associations between comorbidities, symptom burden, inflammatory biomarkers and lung function deterioration in chronic obstructive pulmonary disease (COPD).</p><p><strong>Materials and methods: </strong>Of the 572 COPD subjects initially included in the 2014-2016 Tools for Identifying Exacerbations in COPD study in Sweden, 228 had lung function data at the 7-year follow-up. Symptom burden was assessed by the modified British Medical Research Council scale of dyspnoea (mMRC), the COPD Assessment Test (CAT) and the Clinical COPD Questionnaire (CCQ). Relative lung function decline was assessed as decline in forced expiratory volume in one second (FEV₁) from baseline/year.</p><p><strong>Results: </strong>Lower baseline symptom burden (mMRC, CAT and CCQ), higher FEV₁ and FEV₁% predicted, higher forced vital capacity (FVC) and having atrial fibrillation were associated with larger absolute FEV₁ decline. Associations were found for having atrial fibrillation at baseline and larger relative FEV₁ decline (Beta = -1.60, <i>p</i> = 0.005). Increased symptom burden (value at follow-up minus value at baseline), assessed by mMRC, CAT and CCQ, was positively associated with both larger absolute FEV₁ decline (mMRC: Beta = 6.4, <i>p</i> = 0.009; CAT: Beta = 1.63, <i>p</i> = 0.002; CCQ: Beta = 10.6, <i>p</i> < 0.001) and larger relative FEV₁ decline (mMRC: Beta = 0.44, <i>p</i> = 0.003; CAT: Beta = 0.13, <i>p</i> < 0.002; CCQ: Beta = 0.82, <i>p</i> < 0.001). Moreover, an increase in C-reactive protein (CRP) levels at follow-up was related to larger, both absolute and relative, FEV₁ decline (Beta = 1.14, <i>p</i> = 0.031 and Beta = 0.07, <i>p</i> = 0.019, respectively).</p><p><strong>Conclusions: </strong>Changes in systemic inflammation and symptom burden between two visits were positively associated with a 7-year lung function decline.</p>","PeriodicalId":10704,"journal":{"name":"COPD: Journal of Chronic Obstructive Pulmonary Disease","volume":"22 1","pages":"2525433"},"PeriodicalIF":2.2,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144574978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Respiratory Clinicians' Views on Offering \"Rescue Packs\" to Patients Discharged After COPD Exacerbation: Qualitative Interview Study.","authors":"Karolina Kuberska, Graham Martin, John R Hurst, Mona Bafadhel","doi":"10.1080/15412555.2025.2524346","DOIUrl":"https://doi.org/10.1080/15412555.2025.2524346","url":null,"abstract":"<p><p>\"Rescue packs\" for COPD exacerbations, consisting of a course of antibiotics and steroids, have become part of self-management strategies for many patients living with COPD. Currently, in the UK, rescue packs are guideline-recommended but not routinely offered on hospital discharge. They are, however, commonly prescribed by primary care teams. This study examined hospital-based respiratory clinicians' views on offering patients rescue packs following hospitalisation for COPD exacerbations. We conducted 24 individual and joint semi-structured interviews <i>via</i> telephone or videocall with 30 clinicians (respiratory consultants, respiratory registrars and specialist nurses) in 20 UK hospitals to understand variation in practice around, and views on, offering rescue packs to discharged COPD patients. Interview data were analysed using the constant comparative method. Clinicians' views on offering rescue packs were a mixture of concerns and recognition of potential benefits. Concerns included antimicrobial resistance, individual overuse of antibiotics, and potential side effects of steroids, especially in patients with poorer understanding of their own condition, with lower self-management skills, or who found it difficult to access primary care. Recognised benefits included the potential to prevent future exacerbations, empowering patients by supporting COPD self-management, and circumventing the difficulties of securing an urgent primary care appointment. There was a consensus that supporting patients in self-management of COPD was key to effective care. Given the increasing role of self-management for patients living with COPD, it is vital to ensure that patients are able to appropriately use rescue packs.</p>","PeriodicalId":10704,"journal":{"name":"COPD: Journal of Chronic Obstructive Pulmonary Disease","volume":"22 1","pages":"2524346"},"PeriodicalIF":2.2,"publicationDate":"2025-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144526750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use, Effectiveness, and Safety of Inhaler Devices for LABA/LAMA Fixed-Dose Combinations in Patients with COPD.","authors":"Sara Lopes, Maria Lucia Marino, Filomena Fortinguerra, Nera Agabiti, Valeria Belleudi, Francesco Trotta","doi":"10.1080/15412555.2025.2506548","DOIUrl":"10.1080/15412555.2025.2506548","url":null,"abstract":"<p><p>In Italy, long-acting bronchodilator (LABA/LAMA) fixed-dose combinations are widely used for treating chronic obstructive pulmonary disease (COPD). These medications are available in various inhaler devices, but clinical guidelines do not recommend a specific device, leaving the choice to clinicians based on patient needs. To date, no studies have directly compared the effectiveness and safety of different LABA/LAMA devices. This retrospective observational study evaluated the utilization, effectiveness, and safety of LABA/LAMA inhaler devices in COPD patients in the Lazio region, representing about 10% of Italy's population. Patients aged 45 and older who initiated LABA/LAMA treatment between January 2017 and December 2019 were included. The devices analyzed were dry powder inhalers (DPI) capsule/strip (DPI-<i>t</i>, reference group), DPI with a reservoir (DPI-r), and soft mist inhalers (SMI). The study identified 12,346 eligible patients, with over 80% having prior COPD drug use. Of these, 53.2% used DPI-<i>t</i>, 19.7% DPI-r, and 27.1% SMI. No significant differences in severe exacerbations, mortality, pneumonia, or cerebro-cardiovascular events were observed among the devices. Hazard ratios for key outcomes (e.g., severe exacerbations, mortality) showed overlapping confidence intervals across device types, suggesting no device offered superior effectiveness or safety. This is the first study to assess LABA/LAMA device use in real-world clinical practice for COPD. Findings suggest therapeutic equivalence among devices, supporting flexibility in prescribing. Further research is needed to inform cost-effective prescribing policies for LABA/LAMA therapies.</p>","PeriodicalId":10704,"journal":{"name":"COPD: Journal of Chronic Obstructive Pulmonary Disease","volume":"22 1","pages":"2506548"},"PeriodicalIF":2.2,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144119142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Meta-Analysis Should Not Be Simply Conducted By Default: Biologic Therapy for Chronic Obstructive Pulmonary Disease.","authors":"Jean Bourbeau, Claudia LeBlanc, Bryan Ross, Darcy Marciniuk","doi":"10.1080/15412555.2025.2501548","DOIUrl":"https://doi.org/10.1080/15412555.2025.2501548","url":null,"abstract":"","PeriodicalId":10704,"journal":{"name":"COPD: Journal of Chronic Obstructive Pulmonary Disease","volume":"22 1","pages":"2501548"},"PeriodicalIF":2.2,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144110016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Can Passive Cough Monitoring Predict COPD Exacerbations?","authors":"A H Morice, A C den Brinker, M Crooks, S Thackray-Nocera, O Ouweltjes, R Rietman","doi":"10.1080/15412555.2025.2487909","DOIUrl":"https://doi.org/10.1080/15412555.2025.2487909","url":null,"abstract":"<p><strong>Purpose: </strong>Validation of an alert mechanism for COPD exacerbations based on coughing detected by a stationary unobtrusive nighttime monitor.</p><p><strong>Methods: </strong>This prospective double-blind longitudinal study of cough monitoring included 40 chronic obstructive pulmonary disease (COPD) patients. Participants underwent cough monitoring and completed a daily questionnaire for 12 weeks. If no exacerbation occurred within that period patients were asked to continue being monitored for a further 12 weeks. The automated system identified deteriorating trends in cough based on a personalized cough classifier and the alerts were compared with patient reported exacerbation onsets.</p><p><strong>Results: </strong>Thirty-eight patients [median age 72 (range 57-84)], median FEV-1% predicted 43% (range 20-106%) completed the study and had 41 exacerbations over a total of 3981 days. For 32 patients, the cough monitor data allowed classifier personalization, trend analysis, and alert generation. Based on the trend data, it is estimated that ∼30% of exacerbations are not associated with an increase in cough. The alert mechanism flagged 59% of the exacerbations. For the cases with alerts preceding the onset, the associated lead time was 4 days or more.</p><p><strong>Conclusion: </strong>Though based on a single variable only, the cough-based alert system captured more than half of the exacerbations in a passive, free-living scenario. No adherence issues were reported, and patients confirmed the unobtrusive and hassle-free nature of the approach.</p>","PeriodicalId":10704,"journal":{"name":"COPD: Journal of Chronic Obstructive Pulmonary Disease","volume":"22 1","pages":"2487909"},"PeriodicalIF":2.2,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143986286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Home-Based Inspiratory Muscle Training as Stand-Alone Therapy in COPD: A Randomized Sham-Controlled Trial Assessing Novel and Established Training Methods.","authors":"Martin Hartman, Filip Dosbaba, Ladislav Batalik, Daniela Vlazna, Marek Plutinsky, Kristian Brat, Roberta Catunda Costa, Artur Solon Lima, Lawrence P Cahalin, Magno F Formiga","doi":"10.1080/15412555.2025.2487473","DOIUrl":"10.1080/15412555.2025.2487473","url":null,"abstract":"<p><p>This randomized controlled trial evaluated the effectiveness of two home-based, stand-alone inspiratory muscle training (IMT) modalities - inspiratory flow-resistive loading with biofeedback (IRFL) and mechanical threshold loading (MTL) - compared to a sham MTL group for improving inspiratory muscle performance and functional exercise capacity in COPD patients. Thirty-six COPD patients trained at home for 8 weeks under remote monitoring. Primary outcomes included inspiratory muscle performance assessed <i>via</i> the Test of Incremental Respiratory Endurance (TIRE), functional exercise capacity, lung function, and other COPD-related measures. Both the TIRE IRFL and MTL groups showed significant improvements in inspiratory muscle strength compared to the sham MTL group (<i>p</i> < 0.05). Additionally, the IRFL with biofeedback group demonstrated significant gains in inspiratory muscle work capacity and 6MWT distance compared to both the MTL and sham groups (<i>p</i> < 0.05). No adverse events were reported, and adherence to training protocols was high across all groups. This study supports home-based IMT as a feasible, effective stand-alone intervention for COPD patients, particularly for those who face barriers in accessing traditional pulmonary rehabilitation programs. TIRE IFRL showed superior benefits in enhancing inspiratory muscle function and overall functional exercise capacity compared to fixed-load IMT.</p>","PeriodicalId":10704,"journal":{"name":"COPD: Journal of Chronic Obstructive Pulmonary Disease","volume":"22 1","pages":"2487473"},"PeriodicalIF":2.2,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143802597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alterations in Adiponectin Expression in Models of Cigarette Smoke Extract-Induced Mouse Pulmonary Emphysema and Alveolar Epithelial Cell Injury.","authors":"Siriporn Vongsaiyat Siriphorn, Supitsara Thorsuwan, Julalux Thongam, Sukpattaraporn Ruangklai, Poungpetch Hussarin, Thanaporn Rungruang, Sorachai Srisuma","doi":"10.1080/15412555.2025.2477235","DOIUrl":"10.1080/15412555.2025.2477235","url":null,"abstract":"<p><strong>Purpose: </strong>Cigarette smoke activates lung inflammation and destruction and the development of COPD. Among various factors influenced by lung inflammation, adiponectin produced by lung epithelial cells is thought to play a significant role in regulating inflammation and maintaining tissue integrity. This study aims to examine adiponectin expression in a mouse model of cigarette smoke extract (CSE)-induced emphysema and explore the effects of adiponectin on cell survival and cytokine gene expression in CSE-induced lung epithelial cell damage.</p><p><strong>Methods: </strong>CSE was prepared by passing cigarette smoke through a glass tube containing solvent. PBS or CSE was intraperitoneally administered to C57BL/6 mice. Inflammatory cells, cytokines, adiponectin expression in lung, bronchoalveolar lavage fluid (BALF) and adipose tissue were assessed. CSE and adiponectin were administered to A549 cells to determine cell viability and cytokine gene expression.</p><p><strong>Results: </strong>Intraperitoneal CSE injection significantly increased the mean alveolar linear intercept by 23.11%. CSE significantly increased total cells, macrophages, neutrophils, eosinophils, TNFα, IL-1β levels in BALF. CSE enhanced lung adiponectin protein expression. Treatment of A549 cells with CSE reduced cell survival and adiponectin gene expression. Furthermore, adiponectin treatment enhanced MCP-1 and IL-8 gene expression in A549 cells post-CSE exposure.</p><p><strong>Conclusion: </strong>Intraperitoneal CSE treatment induced lung inflammation, airspace enlargement, and increased adiponectin expression in mice. CSE-exposed A549 cells showed reduced cell viability, upregulated proinflammatory genes, downregulated adiponectin genes. Adiponectin treatment further intensified these genes expressions, aligning with <i>in vivo</i> findings. Elevated adiponectin expression in alveolar epithelial cells suggests its potential role in the development of COPD by enhancing lung inflammation.</p>","PeriodicalId":10704,"journal":{"name":"COPD: Journal of Chronic Obstructive Pulmonary Disease","volume":"22 1","pages":"2477235"},"PeriodicalIF":2.2,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143623970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2025 GOLD Report: What is New and What is Noteworthy for the Practicing Clinician.","authors":"Konstantinos Kostikas, Georgios Hillas, Athena Gogali","doi":"10.1080/15412555.2025.2451613","DOIUrl":"https://doi.org/10.1080/15412555.2025.2451613","url":null,"abstract":"","PeriodicalId":10704,"journal":{"name":"COPD: Journal of Chronic Obstructive Pulmonary Disease","volume":"22 1","pages":"2451613"},"PeriodicalIF":2.2,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143254803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comorbidity Patterns in Chronic Obstructive Pulmonary Disease and Their Associations with Service Utilization.","authors":"Yanran Duan, Hang Fu, Changying Chen, Yaojun Zhao, Shuai Jiang, Chengzeng Wang","doi":"10.1080/15412555.2024.2414793","DOIUrl":"10.1080/15412555.2024.2414793","url":null,"abstract":"<p><strong>Background: </strong>The prevalence of combinations of comorbidities and their associations with inpatient service utilization and readmission among patients with chronic obstructive pulmonary disease (COPD) have not been extensively examined. To address this gap in knowledge, an observational prospective study was conducted using retrospective data.</p><p><strong>Aims: </strong>To identify patterns of comorbidities linked to length of hospital stay, daily expenses, and one-year readmission.</p><p><strong>Methods: </strong>The 30 most common comorbidities were identified in patients with secondary diagnoses using the association rule mining (ARM) method. Regression models were used to examine the relationships between combinations of comorbidities and service utilization, with adjustments for covariates.</p><p><strong>Results: </strong>The five most prevalent comorbidities were pulmonary heart disease (40.99%), ischemic heart disease (38.97%), heart failure (36.77%), hypertension (34.11%), and respiratory disorders (19.12%). Most combinations of comorbidities identified by ARM showed significant associations with an extended length of stay (>13 days), increased daily expenses (>930 CNY), and reduced readmission rates. Among these combinations, glycoprotein metabolism disorder had the strongest association with prolonged length of stay (adjusted odds ratio [aOR]): 1.89, 95% confidence interval [CI]: 1.82-1.95). Conversely, the combination of other brain diseases and respiratory failure was linked to higher daily expenses (aOR: 11.34, 95% CI: 10.58-12.15), and the presence of pulmonary heart disease was associated with elevated one-year readmission rates (aOR: 1.41, 95% CI: 1.37-1.46).</p><p><strong>Conclusion: </strong>Common combinations of comorbidities among inpatients with COPD were identified from an extensive collection of discharge medical records. Furthermore, the associations between comorbidities, inpatient service usage, and readmission rates were determined.</p>","PeriodicalId":10704,"journal":{"name":"COPD: Journal of Chronic Obstructive Pulmonary Disease","volume":"21 1","pages":"2414793"},"PeriodicalIF":2.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142496509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}